Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib phase 3 induction and maintenance study in moderately to severely active Crohn's disease
NL-OMON55819Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of filgotinib in Crohn's disease (8 arms), sponsored by Gilead Sciences. Primary endpoints: Clinical remission by CDAI at Week 10, Endoscopic response at Week 10 and 4 more. Started Mar 2018; status: completed.
02
Drugs
filgotinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON55819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55819.